Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALE Insulin: Liraglutide 3.0 mg in Overweight/Obese T2DM
NCT02963922Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2017
- Primary completion
- Sep 2018
- Modality
- Peptides
- Countries
- 7
01
Overview
A Phase 3 trial of liraglutide in obesity, Overweight, sponsored by Novo Nordisk. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02963922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963922.